A detailed history of Brevan Howard Capital Management LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 48,886 shares of EXEL stock, worth $1.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
48,886
Previous 67,741 27.83%
Holding current value
$1.69 Million
Previous $1.52 Million 16.69%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$21.96 - $27.6 $414,055 - $520,398
-18,855 Reduced 27.83%
48,886 $1.27 Million
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $532,602 - $621,370
26,185 Added 63.01%
67,741 $1.52 Million
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $648,142 - $768,966
32,134 Added 341.05%
41,556 $986,000
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $181,373 - $227,352
9,422 New
9,422 $226,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.1B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.